Condition: Anal High-grade Squamous Intraepithelial Lesion · Anal HSIL · Anal HPV Infection · Sponsor: Frantz Viral Therapeutics, LLC
This is a phase II double blind, placebo-controlled, randomized study of artesunate ointment for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
This description comes directly from the study's public registry record.
Mihaela Plesa · 440-255-1155 · fvtinfo@frantzgroup.com
Ahmad Bayat, MD · 301-956-2523 · ahmadb@amarexcro.com
Always discuss trial participation with your own doctor first.
| Anal Dysplasia Clinic MidWest | Chicago, Illinois, United States | Recruiting |
| Laser Surgery Care | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06206564